#USA #Cambrex #East Rutherford #Snapdragon Chemistry #Q1 Scientific

Cambrex and Partner Awards: A Leap Towards Sustainable Chemistry

In a remarkable achievement for the pharmaceutical industry, Cambrex, a prominent global contract development and manufacturing organization (CDMO), together with its affiliates Snapdragon Chemistry and Q1 Scientific, has been awarded the 2026 Green Chemistry Challenge Award by the American Chemical Society. This award recognizes innovative contributions to greener synthetic pathways in pharmaceutical synthesis, marking a significant step forward in the push for sustainability within the sector.

The recognition stems from the development of a sustainable organocatalytic process utilized for the synthesis of the chiral tetrahydroquinoline core, which is pivotal in the synthesis of obicetrapib. This therapy is currently undergoing late-stage trials and aims to address dyslipidemia, a condition that affects lipid levels in the blood, enhancing the health outcomes for millions.

This innovative method, jointly brought to fruition by Cambrex and NewAmsterdam Pharma, highlights a major evolution in the production process. The organocatalytic synthesis demonstrates improved efficiency and sustainability compared to traditional manufacturing routes, achieving a substantial yield increase while slashing process mass intensity by an impressive 80%. Additionally, this new method has reduced aqueous waste generation, cut manufacturing time by around 70%, and halved production costs, unveiling a paradigm shift towards more eco-friendly industrial practices.

Commitment to Sustainability

Cambrex does not stop there. The company has further solidified its environmental standing through the EcoVadis Gold rating awarded to its Milan facility. This accolade places Cambrex among the top 5% of evaluated organizations for environmental, social, and ethical performance. This recognition is the result of Cambrex's holistic sustainability strategy, which includes an ambitious target to reduce greenhouse gas emissions by 50% by the year 2030 and has already realized a 20% reduction in emissions across its network.

Additionally, Q1 Scientific has engaged in a strategic partnership with Flogas under a Corporate Power Purchase Agreement (CPPA), enabling the company to harness renewable energy generated by the Cronalaght Wind Farm. This initiative aims to meet approximately 50% of the electrical demands at the Waterford site and aligns with the environmental goals of both Q1 Scientific and its community partners, reinforcing Cambrex’s commitment to ecological responsibility.

Leadership in Pharmaceutical Innovation

Thomas Loewald, CEO of Cambrex, voiced his pride in the company’s strides towards environmental sustainability, stating, "At Cambrex, we are dedicated to continually reducing our environmental impact for the benefit of our communities and ensuring long-term, sustainable manufacturing solutions for our customers." His sentiment emphasizes the dual commitment to operational excellence and responsibility towards the environment, two critical elements shaping the future of the pharmaceutical industry.

With over 45 years of experience and a dedicated team of more than 2,000 experts, Cambrex is well-positioned to lead the way in drug substance development and manufacturing across the entire drug lifecycle. Their cutting-edge portfolio encompasses a range of specialized drug substance technologies including advanced methods such as continuous flow chemistry, peptide synthesis, and biocatalysis, underscoring their commitment to pushing the boundaries of innovation while prioritizing sustainability.

As the pharmaceutical landscape evolves, initiatives such as those led by Cambrex not only advance medical science but also reaffirm the industry's moral obligation towards a more sustainable and responsible operational approach. Such recognition and commitment to sustainable practices are not just beneficial but essential for aligning pharmaceutical progress with global environmental targets.

Conclusion

The awards and recognition received by Cambrex, partnered with Snapdragon Chemistry and Q1 Scientific, reflect a growing acknowledgment within the sector that sustainability must be a cornerstone of innovation. As the pharmaceutical industry navigates the challenges of the modern age, organizations such as Cambrex exemplify how to balance commercial success with environmental stewardship, paving the way for a greener future in healthcare.